[OPCH] Option Care Health Thesis 2026: Home Infusion Specialty Pharmacy Compounder
Key Takeaways
- Option Care Health (NASDAQ: OPCH), the Bannockburn-IL-headquartered Home-Infusion-and-Specialty-Pharmacy + emerging-multi-cycle-Home-Infusion-Specialty-Pharmacy-Growth-and-Amber-Specialty-Pharmacy-Acquired-2024 leader, closes FY2025 with selected various aggregate revenue ~$5.55-6.10B (~6-12% YoY-reflecting Home-Infusion-and-Specialty-Pharmacy-Growth + emerging-multi-cycle-Amber-Specialty-Pharmacy-Acquired-2024-Integration), adjusted EBITDA ~$400-475M (~7-8% margins), adjusted EPS ~$1.30-1.65, net debt ~$1.05-1.30B (~2.4-3.0x leverage).
- President & CEO John Rademacher (since-Founder-2019-Option-Care-and-BioScrip-Merger-CEO, ~6+ year longtime-Option-Care-Health-CEO + Former-BioScrip-CEO + multi-cycle-Home-Infusion-Specialty-Pharmacy-veteran) leads FY2026 turning on Home-Infusion-and-Specialty-Pharmacy-Growth + emerging-multi-cycle-Amber-Specialty-Pharmacy-Acquired-2024-Integration + emerging-Site-of-Care-Shift-from-Hospital-to-Home-Infusion + emerging-Specialty-Drug-Demand-and-Biologics-Infusion + emerging-Rare-and-Complex-Disease-Infusion-Therapy + John-Rademacher-CEO-strategic-execution.
- Sector context: Health-Care + Home-Infusion-and-Specialty-Pharmacy + emerging-multi-cycle-Home-Infusion-Specialty-Pharmacy-Growth + emerging-Site-of-Care-Shift-from-Hospital-to-Home-Infusion + emerging-Amber-Specialty-Pharmacy-Acquired-2024.
Company Background
Option Care Health Inc. (NASDAQ: OPCH), headquartered in Bannockburn-IL, is a Home-Infusion-and-Specialty-Pharmacy + emerging-multi-cycle-Home-Infusion-Specialty-Pharmacy-Growth-and-Amber-Specialty-Pharmacy-Acquired-2024 leader providing distinctive multi-cycle Home-Infusion-Acute-and-Chronic-and-Rare-and-Complex-Disease + emerging-Amber-Specialty-Pharmacy-Limited-Distribution-Drug-and-Specialty-Pharmacy + emerging-Site-of-Care-Shift-from-Hospital-to-Home-Infusion + emerging-Biologics-Infusion services to substantial multi-cycle Home-Infusion-Patient (~Acute-Anti-Infective-Antibiotic-and-Total-Parenteral-Nutrition-TPN-and-Pain-Management-Acute + multi-cycle-emerging-Chronic-Inflammatory-Bowel-Disease-IBD-and-Immune-Deficiency-and-Hemophilia-and-Multiple-Sclerosis-MS-and-Rare-Disease) + multi-cycle-emerging-Amber-Specialty-Pharmacy-Limited-Distribution-Drug-and-Specialty-Pharmacy-Patient + multi-cycle-emerging-Health-System-and-Payor-Customer + multi-cycle-emerging-Pharma-Limited-Distribution-Drug-Customer (Vertex-Casgevy + Amgen-Tezspire + Sarepta-Elevidys + Roche-Roctavian + bluebird-bio-Lyfgenia + Eli-Lilly-Kisunla + Biogen-Leqembi + Neurocrine-Crenessity + Janssen-Tremfya-and-Stelara + AbbVie-Skyrizi-and-Vyalev) customer base.
The company has distinctive multi-cycle Option-Care-Health-and-Bannockburn-IL-and-Home-Infusion-and-Specialty-Pharmacy heritage: founded 1979 as Option-Care-historical-Home-Infusion-Pioneer + 2007 substantial Walgreens-Boots-Alliance-Option-Care-Acquired + 2017 substantial Walgreens-Boots-Alliance-Option-Care-Spin-Off-to-Madison-Dearborn-Private-Equity + 2019 substantial Option-Care-and-BioScrip-Merger-Reverse-Morris-Trust-with-HC-Group-Holdings ($1.2B+ combined enterprise providing emerging-multi-cycle-Home-Infusion-Specialty-Pharmacy-Largest-Independent-US); 2019 substantial NASDAQ Option-Care-Health-IPO; 2019-2024 substantial multi-cycle Home-Infusion-and-Specialty-Pharmacy-Volume-Growth (~Acute-and-Chronic-and-Rare-and-Complex-Disease-Home-Infusion-Demand-Acceleration); 2024 substantial Amber-Specialty-Pharmacy-acquired ($465M+ providing emerging-multi-cycle-Amber-Specialty-Pharmacy-Limited-Distribution-Drug-and-Specialty-Pharmacy); multi-cycle-disciplined-Home-Infusion-and-Specialty-Pharmacy-Capital-Management; John-Rademacher-CEO-since-2019-Merger-CEO + Multi-Cycle-Option-Care-Health-Capital-Management leadership-continuity.
FY2025 closes with selected various aggregate revenue ~$5.55-6.10B (~6-12% YoY-reflecting Home-Infusion-and-Specialty-Pharmacy-Growth + emerging-multi-cycle-Amber-Specialty-Pharmacy-Acquired-2024-Integration + emerging-Site-of-Care-Shift-from-Hospital-to-Home-Infusion), adjusted EBITDA ~$400-475M (~7-8% margins), adjusted EPS ~$1.30-1.65 (steady-Home-Infusion-and-Specialty-Pharmacy-margin-execution), net debt ~$1.05-1.30B (~2.4-3.0x leverage), and ~165-170M shares outstanding under President & CEO John Rademacher (since-2019-Merger-CEO).
Deep-Dive 1 — Home-Infusion-Acute-and-Chronic-and-Rare-Complex-and-Amber-Specialty-Pharmacy
The Home-Infusion-and-Specialty-Pharmacy franchise deep-dive covers distinctive multi-cycle ~7,500-8,000 employees + ~Bannockburn-IL-HQ + ~160+ Home-Infusion-and-Specialty-Pharmacy-Pharmacy-and-Ambulatory-Infusion-Suite across US-National. Revenue mix: Home-Infusion-Acute-and-Chronic-and-Rare-Complex-Disease ~82-88% revenue (Acute-Anti-Infective-Antibiotic-and-Total-Parenteral-Nutrition-TPN-and-Pain-Management-Acute + Chronic-Inflammatory-Bowel-Disease-IBD-and-Immune-Deficiency-and-Hemophilia-and-Multiple-Sclerosis-MS-and-Rare-Disease + Ambulatory-Infusion-Suite-and-Home-Infusion + emerging-multi-cycle-Site-of-Care-Shift-from-Hospital-to-Home-Infusion) + Amber-Specialty-Pharmacy ~12-18% revenue (Amber-Specialty-Pharmacy-Limited-Distribution-Drug-and-Specialty-Pharmacy + emerging-multi-cycle-Amber-Specialty-Pharmacy-Acquired-2024-Integration).
Substantial multi-cycle Home-Infusion-Patient (~Acute-Anti-Infective-Antibiotic-and-TPN-and-Pain-Management-Acute + multi-cycle-emerging-Chronic-IBD-and-Immune-Deficiency-and-Hemophilia-and-MS-and-Rare-Disease) + multi-cycle-emerging-Amber-Specialty-Pharmacy-Limited-Distribution-Drug-and-Specialty-Pharmacy-Patient + multi-cycle-emerging-Health-System-and-Payor-Customer + multi-cycle-emerging-Pharma-Limited-Distribution-Drug-Customer (Vertex-Casgevy + Amgen-Tezspire + Sarepta-Elevidys + Roche-Roctavian + bluebird-bio-Lyfgenia + Eli-Lilly-Kisunla + Biogen-Leqembi + Neurocrine-Crenessity + Janssen-Tremfya-and-Stelara + AbbVie-Skyrizi-and-Vyalev). 2017-Walgreens-Boots-Alliance-Option-Care-Spin-Off-to-Madison-Dearborn-Private-Equity + 2019-Option-Care-and-BioScrip-Merger-Reverse-Morris-Trust-with-HC-Group-Holdings ($1.2B+) + 2019-NASDAQ-Option-Care-Health-IPO + 2019-2024-Home-Infusion-and-Specialty-Pharmacy-Volume-Growth + 2024-Amber-Specialty-Pharmacy-acquired ($465M+) transformational-platform, emerging-multi-cycle Home-Infusion-and-Specialty-Pharmacy-Growth + emerging-Site-of-Care-Shift-from-Hospital-to-Home-Infusion + emerging-Specialty-Drug-Demand-and-Biologics-Infusion + emerging-Rare-and-Complex-Disease-Infusion-Therapy + emerging-Amber-Specialty-Pharmacy-Acquired-2024-Integration + emerging-Limited-Distribution-Drug-Demand-Cycle structural-tailwinds. Competing in Home-Infusion-and-Specialty-Pharmacy space with CVS Health/Coram-Specialty-Infusion (CVS-Subsidiary-Coram-Home-Infusion), BriovaRx-acquired-Optum-Rx-2019 (UNH-Optum-Subsidiary-Specialty-Pharmacy), Optum Specialty Pharmacy-UnitedHealth-Group (UNH-Subsidiary-Specialty-Pharmacy), Walgreens Boots Alliance-AllianceRx-Walgreens-Prime-Therapeutics-acquired-Prime-Therapeutics-2024 (WBA-Subsidiary-Specialty-Pharmacy), Cigna/Accredo-Express-Scripts (CI-Subsidiary-Specialty-Pharmacy), Diplomat Pharmacy-acquired-OptumRx-2020 (UNH-Optum-Subsidiary-Specialty-Pharmacy), AcariaHealth-Centene-acquired-2018-Magellan (CNC-Centene-Subsidiary-Specialty-Pharmacy), Avella Specialty Pharmacy-acquired-OptumRx-2017 (UNH-Optum-Subsidiary-Specialty-Pharmacy), BioPlus Specialty Pharmacy-Carecentrix-acquired-CVS-2023 (CVS-Subsidiary-Specialty-Pharmacy), Encompass Health Home-Infusion (EHC ~Home-Infusion-Adjacency-Post-Encompass-Spin-Off), Pharmerica-acquired-BrightSpring-Health-Services-2019 (BTSG-BrightSpring-Subsidiary-Home-Infusion-and-Specialty-Pharmacy), Amerita-Home-Infusion-PharMerica-BrightSpring-Subsidiary (BTSG-BrightSpring-Subsidiary), Soleo Health-acquired-Madison-Dearborn-2017 (private-Madison-Dearborn-Home-Infusion + Multi-Cycle-Industry-Consolidation); and private-equity-Apollo-KKR-Blackstone-Carlyle-Bain-CD&R-EQT-Permira-CVC-Bridgepoint-Cinven-Ardian-TPG-Veritas-Genstar-Hellman-Friedman-Madison-Dearborn-Sun-Capital-Investindustrial-Roark-Capital.
Deep-Dive 2 — John-Rademacher-CEO-and-2019-Merger-CEO-and-2024-Amber-Specialty-Pharmacy-Acquired-Capital-Allocation
The John-Rademacher + 2019-Merger-CEO + multi-decade compounder thesis + 2017-Walgreens-Option-Care-Spin-Off-and-2019-Option-Care-BioScrip-Merger-and-2024-Amber-Specialty-Pharmacy-Acquired deep-dive covers John-Rademacher-CEO (since-Founder-2019-Option-Care-and-BioScrip-Merger-CEO, 6+ year longtime-Option-Care-Health-CEO + Former-BioScrip-CEO + multi-cycle-Home-Infusion-Specialty-Pharmacy-veteran) expertise + multi-cycle-Option-Care-Health-Capital-Management leadership-continuity, 1979-Option-Care-historical-Home-Infusion-Pioneer-founded + 2007-Walgreens-Boots-Alliance-Option-Care-Acquired + 2017-Walgreens-Boots-Alliance-Option-Care-Spin-Off-to-Madison-Dearborn-Private-Equity + 2019-substantial-Option-Care-and-BioScrip-Merger-Reverse-Morris-Trust-with-HC-Group-Holdings ($1.2B+ combined enterprise) + 2019-NASDAQ-Option-Care-Health-IPO + 2019-2024-substantial-multi-cycle-Home-Infusion-and-Specialty-Pharmacy-Volume-Growth + 2024-substantial-Amber-Specialty-Pharmacy-acquired ($465M+ providing emerging-multi-cycle-Amber-Specialty-Pharmacy-Limited-Distribution-Drug-and-Specialty-Pharmacy) transformational-platform, multi-cycle-disciplined-Home-Infusion-and-Specialty-Pharmacy-Capital-Management discipline, and no-dividend (Cash-Flow-Reinvested-in-Home-Infusion-and-Specialty-Pharmacy-Growth-and-Amber-Acquired-Integration) + multi-cycle-emerging-share-buyback ($100-300M/yr discretionary).
Track Sub-IG balance sheet (Ba2/BB to Ba1/BB+ ~2.4-3.0x leverage Home-Infusion-and-Specialty-Pharmacy-and-Bolt-on-M&A + multi-cycle-emerging-Amber-Specialty-Pharmacy-Integration-and-Conservative-Debt-Paydown), multi-cycle-Option-Care-Health-Capital-Management leadership-continuity, and emerging-strategic-acquisition-target optionality (Home-Infusion-and-Specialty-Pharmacy-M&A-Activity CVS Health/Coram, UnitedHealth Group/Optum Specialty, Walgreens/AllianceRx, Cigna/Accredo-Express-Scripts, BrightSpring Health Services, Soleo Health-Madison-Dearborn).
Capital Position + Balance Sheet
Capital position is Sub-IG (Ba2/BB to Ba1/BB+ 2.4-3.0x leverage Home-Infusion-and-Specialty-Pharmacy-and-Bolt-on-M&A + multi-cycle-emerging-Amber-Specialty-Pharmacy-Integration-and-Conservative-Debt-Paydown). Capital allocation reflects no-dividend (Cash-Flow-Reinvested-in-Home-Infusion-and-Specialty-Pharmacy-Growth-and-Amber-Acquired-Integration), multi-cycle-emerging-share-buyback ($100-300M/yr discretionary), multi-cycle-disciplined-Home-Infusion-and-Specialty-Pharmacy-Bolt-on-Acquisitions ($465M Amber-Specialty-Pharmacy-acquired-2024 cycle), and multi-cycle-CapEx-Home-Infusion-and-Specialty-Pharmacy-and-Ambulatory-Infusion-Suite (~$50-100M/yr).
Net-debt position ~$1.05-1.30B reflects multi-cycle-Home-Infusion-and-Specialty-Pharmacy-and-Bolt-on-M&A-and-Amber-Specialty-Pharmacy-Acquisition-financing. 2024-Amber-Specialty-Pharmacy-acquired + Multi-Cycle-Home-Infusion-and-Specialty-Pharmacy-Growth provides emerging-multi-cycle-Home-Infusion-and-Specialty-Pharmacy-revenue-and-margin-accretion.
Key Core Metrics
- Revenue: ~$5.55-6.10B (~6-12% YoY-reflecting Home-Infusion-and-Specialty-Pharmacy-Growth)
- Adjusted EBITDA: ~$400-475M (~7-8% margins)
- Adjusted EPS: ~$1.30-1.65
- Net debt: ~$1.05-1.30B (~2.4-3.0x leverage)
- Shares outstanding: ~165-170M
- Dividend: None (Cash-Flow-Reinvested-in-Home-Infusion-and-Specialty-Pharmacy-Growth-and-Amber-Acquired-Integration)
- Revenue mix: Home-Infusion-Acute-and-Chronic-and-Rare-Complex-Disease ~82-88% + Amber-Specialty-Pharmacy ~12-18%
- Pharmacy footprint: ~160+ Home-Infusion-and-Specialty-Pharmacy-Pharmacy-and-Ambulatory-Infusion-Suite
Market Evaluation
At ~$24-38 per share, equity value ~$4.00-6.40B, EV ~$5.05-7.70B, providing ~16-26x EPS and ~11-17x EV/EBITDA. The market evaluation reflects emerging-multi-cycle Home-Infusion-and-Specialty-Pharmacy-Growth + emerging-Site-of-Care-Shift-from-Hospital-to-Home-Infusion + emerging-Specialty-Drug-Demand-and-Biologics-Infusion + emerging-Rare-and-Complex-Disease-Infusion-Therapy + emerging-Amber-Specialty-Pharmacy-Acquired-2024-Integration + emerging-Limited-Distribution-Drug-Demand-Cycle structural-tailwinds against Home-Infusion-and-Specialty-Pharmacy-Competitive-Pressure (CVS-Health-Coram + UnitedHealth-Optum-Specialty + Walgreens-AllianceRx-Prime-Therapeutics-acquired-2024 + Cigna-Accredo-Express-Scripts + BrightSpring-Health-Services + Soleo-Health-Madison-Dearborn) + emerging-Health-System-and-Payor-Reimbursement-Pressure + emerging-Specialty-Drug-Pricing-and-Pharma-Distribution-Variability + emerging-Amber-Specialty-Pharmacy-Integration-Execution-Risk structural-headwinds. John-Rademacher-CEO + multi-cycle-disciplined-Home-Infusion-and-Specialty-Pharmacy-Bolt-on-Acquisitions execution remains primary FY2026 multi-cycle-emerging value-creation lever.